kleopatraxnibe.blogspot.com
Hematide is in a Phase III trial. Renton led Onyx for nearlu 15 years, stepping down in Februaruy 2008as president, CEO, chairman and a member of Onyx’sx board. At the he helped negotiate a research, developmenft and commercialization partnership with that resulted inthe anti-cancert drug Nexavar. Nexavar tablets, which cost about $5,00 0 a month in the United Statezs and areapproaching $1 billion in annuak sales, are approved in more than 80 countries to treaft kidney cancer and 70-plus countries for live cancer. Prior to joinin Onyx, Renton was president and COO of which acquired Cetusin 1991. Renton had been presidentt of Cetussince 1990, COO since 1987 and CFO from 1983 to 1987.
Rentoj also serves on the boardaof , Cepheid and the Speciaol Olympics of Northern California.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment